Hirsch et al
Based on animal reproduction studies showing fetal harm at clinically relevant exposures, the FDA recommends that semaglutide should be discontinued at least 2 months before a planned pregnancy due to its long washout period (approximately 5 weeks after the last dose)
Educational resources provide patients with comprehensive information about Retatrutide, including usage guidelines, safety information, and treatment expectations
Guentsch A, Preshaw PM, Bremer-Streck S, Klinger G, Glockmann E, Sigusch BW
[1] [3] Key safety considerations include: Bleeding risk assessment : Ensure patients understand signs of bleeding (unusual bruising, blood in urine or stools, prolonged bleeding from cuts) and when to seek help Medication adherence : Address any gastrointestinal side effects promptly to prevent non-adherence to either medication Hydration status : Gastrointestinal adverse effects may cause dehydration, which can affect renal function and potentially impact DOAC clearance or increase risk of acute kidney injury Injection site management : Patients should rotate Ozempic injection sites and avoid injecting into areas with bruising or active bleeding Pancreatitis awareness : Stop Ozempic and seek urgent medical attention if severe persistent abdominal pain radiating to the back occurs Diabetic retinopathy monitoring : Particularly important in patients with pre-existing retinopathy Hypoglycaemia risk : Increased when Ozempic is used with insulin or sulfonylureas Patient education is paramount
GLP-1 (glucagon-like peptide-1) agonists are a breakthrough class of medications originally developed for diabetes management
